Understanding Nalbuphine Hydrochloride API and Its Pharmaceutical Applications

Nalbuphine Hydrochloride is a synthetic opioid compound used as an analgesic in pharmaceutical formulations. For pharmaceutical manufacturers, understanding its pharmacological profile, chemical characteristics, quality requirements and potential applications is important when evaluating the API for product development and commercial manufacturing. Nalbuphine Hydrochloride has the CAS number 23277-43-2 and is listed by Rusan Pharma as a non-pharmacopeial API with DMF available.

What Is Nalbuphine Hydrochloride?

Nalbuphine Hydrochloride is the hydrochloride salt form of nalbuphine, a synthetic phenanthrene opioid. Its pharmacological profile is distinctive because it acts as an agonist at kappa opioid receptors and an antagonist at mu opioid receptors. This mixed agonist-antagonist activity contributes to its analgesic properties and differentiates it from conventional full mu-opioid agonists.

From a chemical perspective, Nalbuphine Hydrochloride has the molecular formula C21H28ClNO4 and a molecular weight of approximately 393.9 g/mol. The compound is identified by CAS No. 23277-43-2, making accurate identification important during API sourcing, development and quality-control processes.

Pharmacological Characteristics of Nalbuphine Hydrochloride

The pharmacological activity of Nalbuphine Hydrochloride is primarily associated with its interaction with opioid receptors. It acts as a kappa receptor agonist and a mu receptor antagonist. This receptor activity gives nalbuphine its analgesic characteristics and has contributed to its application in pain-management formulations.

For pharmaceutical development, understanding the mechanism of action is important because the API’s receptor profile influences its therapeutic role and formulation considerations. As with other opioid-related pharmaceutical ingredients, development and manufacturing require appropriate quality, regulatory and handling controls.

Pharmaceutical Applications of Nalbuphine Hydrochloride

Nalbuphine Hydrochloride is primarily associated with pharmaceutical applications involving pain management. Approved drug information describes nalbuphine hydrochloride injection as a potent analgesic used for the management of pain, including applications involving preoperative and postoperative analgesia.

Its pharmaceutical use is closely linked to injectable formulations. Therefore, manufacturers developing products containing Nalbuphine Hydrochloride need to consider API quality, formulation compatibility, manufacturing controls and applicable regulatory requirements throughout the product-development lifecycle.

API Quality and Regulatory Considerations

API quality is an essential consideration when developing pharmaceutical products. Manufacturers and procurement teams generally evaluate factors such as identity, purity, analytical specifications, and consistency between batches, documentation and regulatory status before selecting an API supplier.

For controlled or opioid-related substances, regulatory compliance and appropriate manufacturing controls become particularly important. Rusan Pharma states that its Ankleshwar API manufacturing facility operates under strict cGMP norms and that the facility is approved by the European EDQM for its APIs.

Rusan Pharma lists Nalbuphine Hydrochloride in its API portfolio as a non-pharmacopeial product with DMF available. This documentation can be relevant to pharmaceutical companies assessing API suppliers for development and commercial requirements.

Choosing a Nalbuphine Hydrochloride API Supplier

Selecting an API supplier involves more than evaluating the availability of a pharmaceutical ingredient. Pharmaceutical companies may consider manufacturing capabilities, quality systems, regulatory documentation, development support, batch consistency and the supplier’s experience with specialised APIs.

For Nalbuphine Hydrochloride, these considerations are particularly relevant because it belongs to a category of pharmaceutical ingredients requiring controlled manufacturing and appropriate regulatory oversight. A supplier with specialised API manufacturing capabilities can support pharmaceutical companies throughout development and commercial supply requirements.

Conclusion

Nalbuphine Hydrochloride is an important opioid-related API with a distinctive kappa agonist and mu antagonist pharmacological profile and established applications in pain-management formulations. Its chemical identity, quality attributes, regulatory documentation and manufacturing controls are important considerations for pharmaceutical manufacturers evaluating the API.

Rusan Pharma includes Nalbuphine Hydrochloride in its API portfolio and provides specialised API manufacturing capabilities supported by cGMP manufacturing infrastructure. For pharmaceutical companies evaluating Nalbuphine Hydrochloride for development or commercial requirements, appropriate technical and regulatory documentation remains an important part of supplier evaluation.